AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32697104
Drug: Intensive outpatient
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive outpatient psychosocial treatment (18-week cognitive-behavioral treatment, two 90-min sessions per week)
Trial: 32697104
Drug: Intensive outpatient
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive outpatient psychosocial treatment
Trial: 35286322
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapy (SMT) plus rifaximin
Trial: 33939512
Drug: Email-only treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Email-only treatment
Trial: 33939512
Drug: Mail-plus-email treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mail-plus-email treatment
Trial: 36209240
Drug: Montreal Cognitive
RxNorm normalized name: BCG, live, Montreal strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montreal Cognitive Assessment (MoCA) administered via telephone
Trial: 36233454
Drug: Sufficient fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sufficient fentanyl (maximum estimated effect site concentration: 7.86 ng/mL)
Trial: 36233454
Drug: Minimum fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Minimum fentanyl (maximum estimated effect site concentration: 1.5 ng/mL)
Trial: 35134703
Drug: Guided internet‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided internet‐based self‐help problem solving therapy intervention
Trial: 34246457
Drug: Homeopathic molecule
RxNorm normalized name: Urtica urens homeopathic preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeopathic molecule for nausea and vomiting prevention during chemotherapy
Trial: 36302537
Drug: Colchicine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (1.5 mg loading dose, followed by 0.5 mg b.i.d. for 6 days and 0.5 mg q.d. for the second week)
Trial: 32641154
Drug: Baricitinib 4
RxNorm normalized name: baricitinib 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib 4 mg orally once daily (OD) on days 1‐14 or until discharge; reduced to 2 mg OD for patients aged >75 years or with creatinine clearance of 30‐60 ml/min.
Trial: 32641154
Drug: Ravulizumab administered
RxNorm normalized name: ravulizumab
DrugBank: Ravulizumab (DB11580)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ravulizumab administered intravenously once according to licensed weight‐based dosing regimen.
Trial: 32165251
Drug: OCA 5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCA 5-10 mg
Trial: 32165251
Drug: OCA 1.5-3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCA 1.5-3.0 mg
Trial: 35365239
Drug: Low-dose DW-MSC
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose DW-MSC (5.0×10^7 cells)
Trial: 35365239
Drug: High-dose DW-MSC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose DW-MSC (1.0×10^8 cells)
Trial: 35946280
Drug: Chromium picolinate
RxNorm normalized name: Chromium Picolinate
DrugBank: Chromium picolinate (DB11255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chromium picolinate supplementation (400 μg daily for 12 weeks)
Trial: 34907435
Drug: Metformin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (0.5 g three times daily)
Trial: 32972733
Drug: OS‐IUI treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OS‐IUI treatment cycles
Trial: 33730517
Drug: 0.3 g·kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 g·kg‐1 body mass sodium bicarbonate (NaHCO3)
Trial: 33730517
Drug: 0.03 g·kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03 g·kg‐1 body mass sodium chloride (PLA)
Trial: 34514494
Drug: Initial invasive
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial invasive treatment (INV)
Trial: 34514494
Drug: Initial conservative
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial conservative treatment (CON)
Trial: 33386335
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (100,000 IU) with dietary calcium intake >300 mg/day
Trial: 33386335
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with dietary calcium intake >300 mg/day
Trial: 35672703
Drug: Intermittent screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent screening and treatment (ISTi)
Trial: 32493693
Drug: Oral roxadustat
RxNorm normalized name: roxadustat
DrugBank: Roxadustat (DB04847)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Oral roxadustat three times weekly
Trial: 32493693
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa injections once weekly
Trial: 32290490
Drug: Concurrent Training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent Training (Zumba Fitness® + muscle-strengthening workout)
Trial: 34019431
Drug: Carboplatin HIPEC
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin HIPEC (800 mg/m2 for 90 minutes)
Trial: 33259451
Drug: Iron isomaltoside
RxNorm normalized name: Iron isomaltoside 1000
DrugBank: Iron isomaltoside 1000 (DB12208)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron isomaltoside administered intravenously over 30 minutes during surgical wound closure
Trial: 33259451
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered intravenously over 30 minutes during surgical wound closure
Trial: 36054180
Drug: High IRSA
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High IRSA (UNa 19-40 mmol/L)
Trial: 36054180
Drug: Intermediate IRSA
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate IRSA (UNa 41-68 mmol/L)
Trial: 36054180
Drug: Low IRSA
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low IRSA (UNa 69-139 mmol/L)
Trial: 34406271
Drug: One leg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One leg, twice a week TENS application
Trial: 34406271
Drug: Two legs,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two legs, twice a week TENS application
Trial: 35347555
Drug: Curcumin supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin supplementation (2.5 g of turmeric 3×/week for 12 weeks)
Trial: 34651206
Drug: 30 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 µg I/kg/day of iodine in oral drops given to 47 infants from their first day of life until hospital discharge
Trial: 34651206
Drug: Control group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group: 47 infants without supplements
Trial: 33675048
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy (ACT), 8 sessions, 90 minutes each
Trial: 33504496
Drug: Liraglutide up
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liraglutide up to 1.8 mg/day
Trial: 33276768
Drug: Perioperative cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative cognitive behavioral therapy (CBT) - six individual sessions, two before and four after surgery.
Trial: 32920973
Drug: Refined rapeseed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refined rapeseed oil (RA) 50 g daily for 8 weeks
Trial: 32920973
Drug: Refined olive
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refined olive oil (OL) 50 g daily for 8 weeks
Trial: 36268379
Drug: 0.3 μg/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 μg/kg/min remifentanil
Trial: 36268379
Drug: 0.1 μg/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 μg/kg/min remifentanil
Trial: 34711182
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of text and phone calls with trained advocates
Trial: 33568118
Drug: 6-week psychosocial
RxNorm normalized name: perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6-week psychosocial support program with oral health educational components
Trial: 32988519
Drug: Chitosan oligosaccharide
RxNorm normalized name: chitosan oligosaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chitosan oligosaccharide (COS) supplementation at 200 mg/kg
Trial: 34803023
Drug: Antibiotics prior
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics prior to skin incision
Trial: 34803023
Drug: Antibiotics after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics after umbilical cord clamping
Trial: 33373036
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg/day for six months
Trial: 32883567
Drug: Empagliflozin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin (10 mg/day, n = 31)
Trial: 32883567
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (n = 18)
Trial: 34020345
Drug: Adjunctive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive therapy (Flunarizine) on standardized IS treatment
Trial: 33685898
Drug: Biapenem 250
RxNorm normalized name: biapenem
DrugBank: Biapenem (DB13028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biapenem 250 mg
Trial: 33685898
Drug: Biapenem 1250
RxNorm normalized name: biapenem
DrugBank: Biapenem (DB13028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biapenem 1250 mg
Trial: 33685898
Drug: Biapenem 1000
RxNorm normalized name: biapenem
DrugBank: Biapenem (DB13028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biapenem 1000 mg
Trial: 32367561
Drug: Immediate periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate periodontal therapy (oral hygiene instructions and single-visit scaling and root planing)
Trial: 32367561
Drug: Delayed periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed periodontal treatment (control group)
Trial: 34420834
Drug: Zonisamide 50
RxNorm normalized name: zonisamide 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zonisamide 50 mg/day (flexible dosing)
Trial: 33600189
Drug: l-homocysteine aptamer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-homocysteine aptamer (randomized SELEX)
Trial: 33600189
Drug: l-homocysteine selection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-homocysteine selection (redirected SELEX)
Trial: 32980764
Drug: Hyperbaric ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric ropivacaine (9.5, 11, 12.5, 14, or 15.5 mg)
Trial: 34980198
Drug: Sildenafil (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (25 mg orally three times a day for seven days)
Trial: 34980198
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical capsules, same dosage and duration)
Trial: 36342059
Drug: Mindfulness therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness therapy (8-week face-to-face group program)
Trial: 34404324
Drug: Neural mobilization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neural mobilization through mirror therapy (MT)
Trial: 32758384
Drug: early parenteral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: early parenteral nutrition (early-PN)
Trial: 32758384
Drug: late parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: late parenteral nutrition (late-PN)
Trial: 33444161
Drug: Insulin Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin Glargine 300 units · mL-1 (Gla-300)
Trial: 33444161
Drug: Insulin Degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin Degludec 100 units · mL-1 (Deg-100)
Trial: 35643381
Drug: Shen-Yuan-Dan (SYD)
RxNorm normalized name: Ren shen
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shen-Yuan-Dan (SYD) capsules (4 capsules, 3 times a day, with a further 4 capsules 2 hours before PCI)
Trial: 35643381
Drug: Shen-Yuan-Dan (SYD)
RxNorm normalized name: Ren shen
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shen-Yuan-Dan (SYD) capsules
Trial: 32794482
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy (triple therapy + colloidal bismuth subcitrate)
Trial: 32794482
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (amoxicillin, clarithromycin, and omeprazole)
Trial: 32307124
Drug: Counseling intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Counseling intervention implemented at the hospital level for medication storage
Trial: 32307124
Drug: Counseling intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Counseling intervention for medication storage after adjusting for time
Trial: 36124653
Drug: Hydrogen inhalation
RxNorm normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogen inhalation and hydrogen dissolved in water
Trial: 36124653
Drug: Placebo air
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo air inhalation
Trial: 32109880
Drug: Frequent carbohydrate
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frequent carbohydrate ingestion (15 × 5 g every 5 min)
Trial: 32109880
Drug: Late bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late bolus carbohydrate ingestion (1 × 75 g after 75 min)
Trial: 35304280
Drug: Inhaled ciclesonide
RxNorm normalized name: ciclesonide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled ciclesonide
Trial: 34560906
Drug: Ixekizumab (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixekizumab (both dosing regimens)
Trial: 35931598
Drug: Povidone iodine
RxNorm normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone iodine (PI) disinfecting solution
Trial: 34625041
Drug: Aripiprazole lauroxil
RxNorm normalized name: Aripiprazole lauroxil
DrugBank: Aripiprazole lauroxil (DB14185)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aripiprazole lauroxil (AL) 1064 mg q8wk
Trial: 34625041
Drug: Paliperidone palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paliperidone palmitate (PP) 156 mg q4wk
Trial: 34117400
Drug: Single site
RxNorm normalized name: Seprafilm Single Site
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single site phacotrabeculectomy with MMC 0.2 mg/mL
Trial: 34117400
Drug: Twin-site phacotrabeculectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twin-site phacotrabeculectomy with MMC 0.2 mg/mL
Trial: 34076495
Drug: Pluchea indica
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pluchea indica tea (PIT) 1.5g once daily for 12 weeks
Trial: 34076495
Drug: Camellia sinensis
RxNorm normalized name: Camellia Sinensis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camellia sinensis tea (CST) 1.5g once daily for 12 weeks
Trial: 33377218
Drug: Inhaled nebulised
RxNorm normalized name: Hydra-Neb Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nebulised unfractionated heparin (UFH)
Trial: 32270637
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with opioid drugs (Oxycodone hydrochloride prolonged-release tablet)
Trial: 32270637
Drug: Oxycodone hydrochloride
RxNorm normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone hydrochloride prolonged-release tablet (Control group)
Trial: 33547453
Drug: Exposure to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure to online misinformation about COVID-19 vaccines
Trial: 33547453
Drug: Factual information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Factual information about COVID-19 vaccines
Trial: 32652432
Drug: Magnetic resonance
RxNorm normalized name: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnetic resonance enterography and colonography (MREC) with water enema and intravenous spasmolytics
Trial: 36397216
Drug: Huayu Tongluo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huayu Tongluo moxibustion combined with intradermal needling (6 times a week for 4 weeks)
Trial: 36397216
Drug: Western medication
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medication (paroxetine hydrochloride tablets, 20 mg once daily for 4 weeks, max 40 mg/d)
Trial: 36067489
Drug: Macleaya cordata
RxNorm normalized name: Tilia cordata pollen
DrugBank: Tilia cordata pollen (DB10954)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Macleaya cordata extract (MCE) at 100 mg/kg
Trial: 33864634
Drug: Octanoic acid
RxNorm normalized name: Octanoic acid
DrugBank: Caprylic acid (DB04519)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octanoic acid (OA) treatment over a 2-week period
Trial: 32151101
Drug: Bite splint
RxNorm normalized name: PAD,BITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bite splint + Platelet-rich plasma injection
Trial: 32151101
Drug: Bite splint
RxNorm normalized name: PAD,BITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bite splint + Sodium hyaluronate injection
Trial: 32151101
Drug: Bite splint
RxNorm normalized name: PAD,BITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bite splint + Betamethasone injection
Trial: 35807872
Drug: Cocoa flavanols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa flavanols (CF) 790 mg
Trial: 33430841
Drug: KalobaTUSS® syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KalobaTUSS® syrup
Trial: 36148830
Drug: 4L single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4L single dose polyethylene glycol (PEG) given in the evening before
Trial: 36148830
Drug: 4L split-dose
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4L split-dose PEG
Trial: 36148830
Drug: 2L split-dose
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2L split-dose PEG (+ bisacodyl 15 mg)
Trial: 36148830
Drug: 2L single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2L single dose PEG (+ bisacodyl 15 mg) in the morning
Trial: 32068975
Drug: 6-month intervention
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month intervention consisting of 2 hours of physical exercise, cognitive training, and classroom study or rest once weekly
Trial: 34837758
Drug: Group Acceptance
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Acceptance and Commitment Therapy (G‐ACT)
Trial: 32917192
Drug: 6% hydrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% hydrogen peroxide gel
Trial: 35537858
Drug: Cannabidiol (CBD)
RxNorm normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabidiol (CBD) 20 mg/kg/d, b.i.d. for 4 weeks
Trial: 35724828
Drug: Doxycycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (100 mg/day) and Zinc (15 mg/day)
Trial: 35724828
Drug: Single-dose treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose treatment with Doxycycline
Trial: 35288227
Drug: Postoperative irradiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative irradiation plus adjuvant systemic therapy
Trial: 35288227
Drug: Adjuvant systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant systemic therapy alone
Trial: 33673616
Drug: Melatonin rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin rinse solution
Trial: 33673616
Drug: Placebo rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo rinse solution
Trial: 33546733
Drug: AANmDOF robotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AANmDOF robotic training (combination of training in LOPES‐II and conventional gait training, 30 min, 3–5 times a week for 6 weeks)
Trial: 36078940
Drug: 4.4 MHz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.4 MHz Radiofrequency (RF) therapy
Trial: 37079158
Drug: Iodine intake
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodine intake estimated from 24‐h urinary iodine excretion (UIE)